Retatrutide vitamin B12 interaction and supplementation is an emerging clinical consideration for patients enrolled in trials of this investigational triple agonist medicine. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing marked reductions in appetite and food intake. These same effects may reduce dietary B12 consumption over time, particularly from animal-derived foods. Although a direct pharmacological link between retatrutide and B12 deficiency has not been confirmed, mechanistic parallels with approved GLP-1 medicines — combined with the risk of prolonged dietary restriction — make proactive nutritional monitoring a prudent and clinically responsible approach.

How Retatrutide May Affect Vitamin B12 Absorption

Retatrutide's primary B12 risk is indirect: its substantial reduction in food intake may lower dietary B12 consumption over time, though no direct pharmacological effect on intrinsic factor or B12 absorption has been confirmed.

Retatrutide is an investigational triple agonist medicine that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This combined mechanism produces substantial reductions in appetite, caloric intake, and body weight, as demonstrated in phase 2 clinical trial data published in the New England Journal of Medicine.^[7] However, the same physiological changes that make retatrutide potentially effective for weight management may also influence how the body obtains certain micronutrients, including vitamin B12.

Vitamin B12 absorption is a complex, multi-step process that depends on adequate gastric acid secretion and the production of intrinsic factor by the stomach's parietal cells. GLP-1 receptor agonism is known to slow gastric emptying — a pharmacological effect shared by retatrutide — though slowed gastric emptying does not directly impair intrinsic factor production or B12 absorption per se.^[4][5] The principal hypothesised risk is indirect: the marked reduction in food intake associated with retatrutide use may significantly lower dietary B12 consumption over time, particularly from animal-derived foods. This pathway is theoretical and patient-dependent; a direct, regulatory-confirmed causal link between retatrutide and vitamin B12 deficiency has not been established.

Retatrutide has not yet received marketing authorisation from the MHRA or EMA and remains under clinical investigation. Nevertheless, the mechanistic parallels with approved GLP-1 medicines — combined with the substantial dietary restriction retatrutide may induce — make nutritional vigilance a reasonable and prudent clinical consideration. Any suspected adverse effects in patients receiving retatrutide as part of a clinical trial should be reported via the MHRA Yellow Card scheme.

Why Vitamin B12 Deficiency Is a Concern With GLP-1 Medicines

Reduced appetite from GLP-1-based medicines can lower intake of animal-derived B12 sources; risk is highest in older adults, vegans, metformin users, and those on long-term PPIs or with gastrointestinal conditions.

Evidence from approved GLP-1 receptor agonists, such as semaglutide and liraglutide, provides a useful framework for understanding potential nutritional risks associated with retatrutide. Patients using these medicines may experience markedly reduced appetite and food intake, which could — in susceptible individuals — lead to inadequate consumption of animal-derived foods, the primary dietary sources of vitamin B12. It is important to note that a direct, well-established causal link between GLP-1 receptor agonist use and clinically significant B12 deficiency has not been confirmed in the published literature; the risk is considered patient-dependent and largely mediated through reduced dietary intake rather than a pharmacological effect on absorption.

The concern is amplified in specific patient groups who are already at elevated risk of B12 deficiency, including:

• Older adults, in whom gastric acid secretion naturally declines with age

• Individuals following vegetarian or vegan diets, who may have limited dietary B12 intake

• Those taking metformin, a commonly co-prescribed medicine for type 2 diabetes that is independently associated with reduced B12 absorption — the MHRA Drug Safety Update (2022) advises monitoring B12 in symptomatic or at-risk patients taking metformin^[13]

• Patients taking long-term proton pump inhibitors (PPIs) or H2-receptor antagonists, which reduce gastric acid and may impair B12 release from food

• Patients with a history of gastrointestinal surgery, including bariatric procedures

• Those with pernicious anaemia or other autoimmune conditions affecting intrinsic factor production

• Patients with coeliac disease, inflammatory bowel disease, or significant alcohol use, which may impair absorption

Vitamin B12 plays an essential role in red blood cell formation, neurological function, and DNA synthesis. Prolonged deficiency can result in megaloblastic anaemia and, critically, irreversible neurological damage if left untreated.^[8][14] Because the body stores B12 in the liver for several years, deficiency may develop insidiously, with symptoms appearing only after stores are substantially depleted. This delayed presentation makes proactive monitoring particularly important in patients receiving medicines that reduce dietary intake over extended periods.

Recognising the Signs of Low Vitamin B12 Levels

B12 deficiency presents with neurological symptoms — tingling, balance problems, cognitive changes — and haematological symptoms such as fatigue and pallor; neurological damage can be irreversible even when anaemia is absent.

Vitamin B12 deficiency can present with a wide and sometimes non-specific range of symptoms, which may be easily attributed to other causes — including the fatigue and dietary changes that commonly accompany weight-loss treatment. Clinicians and patients should therefore maintain a low threshold for investigation, particularly in those with identifiable risk factors.

Neurological symptoms are among the most clinically significant and may include:

• Tingling, numbness, or a 'pins and needles' sensation in the hands and feet

• Difficulty with balance and coordination (sensory ataxia)

• Memory problems, cognitive slowing, or confusion

• Mood changes, including low mood or irritability

Haematological symptoms may include:

• Persistent fatigue and weakness

• Breathlessness on exertion

• Pallor or a slightly yellowish tinge to the skin

• A sore, inflamed tongue (glossitis)

It is worth emphasising that neurological damage from B12 deficiency — including subacute combined degeneration of the spinal cord — can progress and become irreversible if treatment is delayed, even in cases where anaemia is absent.^[9][10] This dissociation between haematological and neurological manifestations means that a normal full blood count does not exclude clinically significant B12 deficiency.

If neurological symptoms are present — particularly gait disturbance, sensory ataxia, or progressive limb weakness — urgent assessment should be arranged and intramuscular hydroxocobalamin treatment initiated without delay, in line with NICE CKS and BSH guidance on cobalamin and folate disorders. Patients who develop any of the above symptoms during retatrutide treatment should contact their GP promptly rather than waiting for a scheduled review. Early identification and treatment of deficiency is essential to prevent long-term harm.

When and How to Supplement Vitamin B12 Safely

Oral cyanocobalamin 50–150 mcg daily is recommended for dietary deficiency; intramuscular hydroxocobalamin is preferred for malabsorption, pernicious anaemia, or severe symptomatic deficiency, per BNF and NICE CKS guidance.

The decision to supplement vitamin B12 during retatrutide treatment should be guided by baseline blood levels, the underlying cause of any deficiency, individual risk factors, and clinical judgement. There is no universal recommendation to supplement all patients receiving GLP-1-based therapies, but supplementation is appropriate and advisable in those with confirmed deficiency, borderline levels, or multiple risk factors for depletion.

Before committing to long-term supplementation, clinicians should establish the underlying cause of deficiency — in particular, whether pernicious anaemia is present (assessed by testing for anti-intrinsic factor antibodies and, where appropriate, anti-parietal cell antibodies), as this determines the treatment route and duration.

Oral supplementation with cyanocobalamin is appropriate for patients whose deficiency is due to dietary insufficiency and in whom absorption is not impaired. UK guidance (NICE CKS; BSH) recommends oral cyanocobalamin at doses of 50–150 micrograms daily, taken between meals.^[14][15] High-dose oral B12 (which may be used in some specialist settings) can be absorbed passively through the gut wall even in the absence of intrinsic factor, but this approach is not standard first-line UK practice for most patients.

Note on methylcobalamin: Methylcobalamin is not routinely recommended or licensed as a medicine in the UK. Hydroxocobalamin (intramuscular) and cyanocobalamin (oral) are the standard UK preparations.

Intramuscular (IM) hydroxocobalamin is the preferred route in the UK for patients with confirmed malabsorption (e.g., pernicious anaemia, post-gastrointestinal surgery), severe or symptomatic deficiency, or poor adherence to oral supplementation. UK dosing schedules, per BNF and NICE CKS, are as follows:

• Without neurological involvement: 1 mg IM three times a week for 2 weeks, then 1 mg IM every 2–3 months^[14][15]

• With neurological involvement: 1 mg IM on alternate days until no further improvement, then 1 mg IM every 2 months

Patients should not self-initiate supplementation without first discussing it with their GP or prescribing clinician. Dietary advice — including encouraging consumption of B12-rich foods such as eggs, dairy, meat, and fortified plant-based alternatives — should accompany any supplementation strategy.

Monitoring Vitamin B12 During Retatrutide Treatment

Baseline serum B12, full blood count, and folate should be measured before starting retatrutide; higher-risk patients should be rechecked at six to twelve months and annually thereafter.

Given the potential for reduced dietary intake and the mechanistic similarities retatrutide shares with approved GLP-1 medicines, a structured approach to nutritional monitoring is clinically sensible for patients receiving this treatment. The following represents pragmatic, expert-informed guidance in the absence of retatrutide-specific monitoring protocols; it should be adapted as clinical evidence evolves.

At baseline, clinicians should consider measuring:

• Serum vitamin B12 — UK laboratories typically report results in pmol/L; deficiency is generally defined as below 148 pmol/L, with a borderline range of approximately 148–258 pmol/L (reference intervals vary between laboratories and should be interpreted accordingly).^[14][15] Borderline results warrant further assessment rather than reassurance alone.

• Holotranscobalamin (active B12) — where available, this is a more sensitive early marker of B12 depletion and may be preferred in some settings^[12][15]

• Full blood count — to identify macrocytosis or anaemia

• Folate levels — as folate deficiency can co-exist and confound the clinical picture

• Methylmalonic acid (MMA) and homocysteine — functional markers of B12 status, useful when serum B12 is borderline; note these are typically specialist tests, may not be universally available, and can be confounded by renal impairment (MMA) or other nutritional deficiencies (homocysteine)

• Anti-intrinsic factor antibodies (± anti-parietal cell antibodies) — when pernicious anaemia is clinically suspected

During ongoing treatment, monitoring frequency should be tailored to individual risk. A reasonable approach for higher-risk patients — such as those taking metformin, older adults, or those with very low dietary intake — would be to recheck B12 levels at six to twelve months and annually thereafter. For lower-risk patients with adequate dietary intake and no confounding factors, annual review may suffice. These intervals represent expert opinion given the absence of retatrutide-specific evidence.

Clinicians should document nutritional monitoring as part of the overall treatment plan and ensure patients are aware of the importance of reporting new symptoms between scheduled reviews.

Guidance From NHS and NICE on Nutritional Monitoring

NICE CKS and BSH guidelines on B12 and folate deficiency provide the current applicable framework; retatrutide-specific NICE guidance is pending any future MHRA licensing decision.

Whilst NICE has not yet issued specific guidance on retatrutide — reflecting its investigational status — existing NICE and NHS frameworks for GLP-1 receptor agonists and nutritional deficiency management provide a relevant and applicable foundation for clinical practice.

NICE Clinical Knowledge Summary (CKS) on anaemia due to B12 and folate deficiency, alongside the BSH guideline on the diagnosis and treatment of cobalamin and folate disorders, outline clear thresholds for investigation and treatment. These resources recommend that clinicians consider B12 deficiency in any patient presenting with relevant symptoms or risk factors, and that treatment — particularly intramuscular hydroxocobalamin — should not be delayed pending specialist review when deficiency is confirmed and symptomatic, especially where neurological involvement is present.^[15]

For patients undergoing significant dietary restriction — as may occur with retatrutide — guidance from the British Obesity and Metabolic Surgery Society (BOMSS) on post-bariatric nutritional monitoring offers a useful parallel, recommending routine monitoring of B12, iron, folate, and vitamin D. This analogy should be interpreted with caution: retatrutide is a pharmacological intervention, not a surgical procedure, and the degree of nutritional risk may differ. Routine multivitamin supplementation is not automatically indicated for patients on GLP-1-based therapies unless clinically warranted; supplementation decisions should be individualised.

Patients and clinicians are encouraged to:

• Report any new neurological or haematological symptoms promptly to a GP, and seek urgent assessment if neurological symptoms are present

• Discuss nutritional supplementation as part of the initial treatment consultation

• Refer to a dietitian where dietary intake is significantly restricted or where multiple deficiencies are identified

• Report suspected adverse drug reactions — including any nutritional concerns potentially related to retatrutide — via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk)

• Stay informed as MHRA and NICE guidance evolves following any future licensing decision for retatrutide

Proactive nutritional monitoring is a cornerstone of safe, responsible prescribing for any medicine that substantially alters dietary behaviour, and retatrutide should be no exception.

Frequently Asked Questions